Effectiveness of first-line empirical treatments according to duration
| ITT eradication rate | PP eradication rate | mITT eradication rate | ||||||||||
| Treatment duration | Treatment duration | Treatment duration | ||||||||||
| N | 7 days | 10 days | 14 days | N | 7 days | 10 days | 14 days | N | 7 days | 10 days | 14 days | |
| PPI-C+A* | 8337 | 60.4% | 71.5% | 73.2% | 6647 | 83.0% | 84.8% | 86.7% | 6743 | 82.7% | 84.2% | 86.2% |
| PPI-C+M* | 1039 | 74.0% | 57.4% | 54.3% | 898 | 84.8% | 67.3% | 67.9% | 903 | 84.4% | 66.7% | 67.9% |
| PPI-A+M | 561 | 69.3% | 77.4% | 25.0% | 458 | 80.7% | 85.9% | 80.0% | 463 | 80.8% | 85.7% | 80.0% |
| PPI-A+L | 404 | 8.6% | 78.0% | 74.2% | 371 | 8.9% | 86.8% | 85.2% | 382 | 8.8% | 85.4% | 85.2% |
| PPI-C+A+T seq | 1158 | NA | 77.5% | NA | 957 | NA | 92.1% | NA | 969 | NA | 91.5% | NA |
| PPI-C+A+M seq* | 620 | NA | 74.4% | NA | 528 | NA | 82.9% | NA | 569 | NA | 80.8% | NA |
| PPI-C+A+T conc | 187 | NA | 85.4% | 89.5% | 162 | NA | 95.5% | 100.0% | 167 | NA | 92.8% | 100.0% |
| PPI-C+A+M conc | 4164 | NA | 84.8% | 88.2% | 3891 | 95.0% | 88.9% | 92.2% | 3992 | 90.9% | 88.3% | 92.1% |
| PPI-C+A+B | 1743 | 50.0% | 74.6% | 86.6% | 1577 | 76.9% | 86.6% | 92.6% | 1594 | 76.9% | 86.2% | 92.4% |
| PPI-M+Tc+B | 192 | NA | 75.3% | 83.3% | 157 | NA | 93.8% | 88.2% | 159 | NA | 93.1% | 88.2% |
| PPI-M+D+B | 59 | NA | 93.8% | 78.0% | 54 | NA | 93.3% | 81.1% | 58 | NA | 93.8% | 80.0% |
| PPI+single capsule† | 1300 | NA | 82.1% | NA | 1102 | NA | 95.4% | NA | 1124 | NA | 94.5% | NA |
| Other | 1449 | 62.1% | 73.4% | 54.5% | 1073 | 73.7% | 85.0% | 60.4% | 1094 | 73.7% | 84.4% | 59.7% |
| Total | 21 213 | 61.1% | 76.9% | 79.6% | 17 875 | 78.5% | 87.8% | 88.3% | 18 217 | 78.2% | 87.0% | 88.0% |
*An effectiveness univariate analysis was performed accounting 10-day or 14-day treatments prescribed together with high doses PPI only, and following therapies reached over 90% mITT eradication rate: 14-day PPI-C+A (89.6%), 10-day PPI-C+A+M seq (91.6%), 10-day or14-day PPI-C+A+M conc (both 92.7% and 92.8%), 10-day PPI-C+A+B (95.5%), 10-day PPI-M+Tc+B (95.2%). A χ2 test was also performed and significant comparisons (10 days vs 14 days with high-dose PPIs) were reported in the table (*). Additional pair-wise comparison (by means of Chi2 test and Fisher exact test) were performed between following treatments: 10-day sequential, 14-day concomitant and 10-day bismuth quadruple: statistically significant differences (p<0.001) were found in all comparisons in favour of the 14-day concomitant and 10-day bismuth quadruple therapies.
†Three-in-one single capsule containing bismuth, tetracycline and metronidazole.
A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; ITT, intention-to-treat; L, levofloxacin; M, metronidazole; mITT, modified-intention-to treat; NA, Not applicable; PP, per protocol; PPI, proton pump inhibitor; Seq, sequential; Tc, tetracycline.